U.S. Markets open in 7 hrs 1 min
  • S&P Futures

    4,220.00
    +10.25 (+0.24%)
     
  • Dow Futures

    33,365.00
    +61.00 (+0.18%)
     
  • Nasdaq Futures

    13,357.75
    +46.50 (+0.35%)
     
  • Russell 2000 Futures

    1,982.50
    +6.20 (+0.31%)
     
  • Crude Oil

    93.90
    -0.44 (-0.47%)
     
  • Gold

    1,807.00
    -0.20 (-0.01%)
     
  • Silver

    20.34
    -0.00 (-0.02%)
     
  • EUR/USD

    1.0318
    -0.0007 (-0.0722%)
     
  • 10-Yr Bond

    2.8880
    0.0000 (0.00%)
     
  • Vix

    20.20
    +0.46 (+2.33%)
     
  • GBP/USD

    1.2193
    -0.0010 (-0.0793%)
     
  • USD/JPY

    133.3450
    +0.3460 (+0.2602%)
     
  • BTC-USD

    23,943.98
    -649.95 (-2.64%)
     
  • CMC Crypto 200

    569.09
    -5.65 (-0.98%)
     
  • FTSE 100

    7,465.91
    -41.20 (-0.55%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

UNITY Biotechnology Reports Granting of New Employment Inducement Award

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Unity Biotechnology, Inc.
Unity Biotechnology, Inc.

SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from June 14, 2022, through June 28, 2022, the Compensation Committee of the Board of Directors (the “Board”) granted a new employee a stock-based award covering an aggregate of 30,000 shares of UNITY common stock, including options to purchase an aggregate of 30,000 shares of UNITY common stock. The stock-based award was granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).

About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Media Contact:
Canale Communications
Jason Spark
jason.spark@canalecomm.com

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com